Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • ThePresident
    Member
    • Jun 2012
    • 72

    #1

    Understanding VCF output from mpileup

    Hello,

    As a start, I would like to mention that I just passed 2 hours reading older threads here and on biostar as well as the VCF specification sheet.

    That been said, I have a question upon calling a SNPs from RNA-seq data (Illumina signle-read, bacterial) with mpileup. I got my VCF file and I'm struggling a little bit to understand the output. If I have:

    Code:
    gi|xxx|emb|xxx|	143630	.	C	T	999	.	DP=490	VDB=0.0004	AF1=1	AC1=4	DP4=1,0,211,276	MQ=20	FQ=-286	PV4=0.43,1.5e-11,1,0.048		GT:PL:GQ	1/1:255,255,0:99	1/1:255,255,0:99
    I'm pretty sure of the following:
    1. 143630 is the position of my SNPs
    2. C is the base in the reference genome and T the alternate variant (actual SNPs)
    3. 999 is the score. The higher it is, better the chances that the call is genuine
    4. DP is the actual coverage on that specific position
    5. DP4 are reads fwd and rev for reference and fwd and rev for alternate call
    6. MQ is the quality


    Now, here are my questions:
    1. VDB is supposed to be Variant Distance Bias. What exaclt does it means and how I interpret it?
    2. AF1 is Allele Frequency. By 1 it means that all the reads are calling the SNPs? If I have AF1=0.5, it means that half of the reads are calling ref nucleotide while the other half is calling SNP?
    3. What the heck is AC1? Max likelihood okay, but how you interpret it?
    4. How do you interpret FQ (Phred probability), i.e. lower vs higher?
    5. PV4 is a total mess... Any insight would be greatly appreciated.
    6. GT:PL:GQ: same as above.


    I know that this is probably very basic for most of you, but I'm just trying to make some sense out of it...

    Thank you all in advance,

    TP

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
17 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-13-2026, 09:56 AM
0 responses
22 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-09-2026, 11:14 AM
0 responses
28 views
0 reactions
Last Post SEQadmin2  
Working...